Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.

Trial Profile

Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azelastine/fluticasone-propionate (Primary) ; Azelastine; Fluticasone propionate
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 23 Oct 2015 According to the media release of Meda Pharmaceuticals, based on the data from this and other two trials (CTP: 32910 and 37579) Dymista nasal spray (azelastine hydrochloride/fluticasone propionate) was approved by Health Canada for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis.
    • 15 Jun 2011 Results were presented at the European Academy of Allergy and Clinical Immunology (EAACI).
    • 04 Apr 2011 Results from this trial were used to support an NDA in the US.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top